Strengthening the Consumer Healthcare Product Lineup

「In fiscal 2025, we launched new products including Hepalyse Gastrointestinal Oral Solution EX and Hepalyse Gastrointestinal Drink in the Hepalyse series, IONA F Night Wrapping Pack and IONA R Double Action Cream in the IONA basic skincare series, and Hepalyse WT and Chondro Support Active for Taiwan.」

「2025年度はヘパリーゼシリーズの「ヘパリーゼ胃腸内服液EX」「ヘパリーゼ胃腸ドリンク」、基礎化粧品イオナシリーズの「イオナ エフ ナイトラッピング パック」「イオナ Ｒ ダブルアクションクリーム」、台湾向けとして「ヘパリーゼWT」、「コンドロサポートアクティブ」を新製品として発売いたしました。」

「During the interim consolidated accounting period, we launched new products including Hepalyse Gastrointestinal Oral Solution EX, Hepalyse Gastrointestinal Drink and IONA F Night Wrapping Pack.」

「In September, we began shipping Hepalyse W Shine, a new product in the Hepalyse W series scheduled for launch in October 2024.」

「During fiscal 2023, we launched new products including Prevalin α Quick Ointment and Prevalin α Quick Cream, treatments for skin disorders.」

「Sales also increased for the Western herbal medicine range, including Prefemin, a treatment for premenstrual syndrome (PMS) that was reclassified as a Class 2 OTC drug in April 2023, and the Masdent range of medicated toothpaste for periodontal disease and bad breath.」

「We worked to strengthen the product lineup and launched new products including Haizerry Granules EX, a tonic health supplement containing royal jelly as an active ingredient, and Viewclear Hi40 Active, an eye drop containing chondroitin.」

「During the nine-month period ended the third quarter, we launched IONA Spa & Mineral W Cleansing and Belfemin, a Western herbal medicine.」

「During the nine-month period ended the third quarter, we began sales of products including Chondramine Ca tablets and Prevalin MyCare. In addition, in November 2020, we obtained manufacturing and marketing approval for Belfemin, a treatment for leg swelling caused by mild venous insufficiency. We will continue working to expand products that meet market needs.」

「During the six-month period ended the second quarter, we began sales of products including Chondramine Ca tablets and Prevalin MyCare. We will continue working to expand products that meet market needs.」

「In March 2020, we launched Hepalyse W Carbonated, strengthening the product lineup.」

「In June 2019, we rolled out Hepalyse W Jelly nationwide, strengthening the product lineup.」

「In June 2019, we rolled out Hepalyse W Jelly nationwide, strengthening the product lineup.」

「During the consolidated fiscal year, we launched 3 new products, Hepalyse W Premium Kiwami, Hepalyse Super Rich and Hepalyse W Jelly (jelly), strengthening the product lineup.」

「In April 2018, we launched Hepalyse W Premium Kiwami as the top-end product in the Hepalyse W series, strengthening the product lineup.」

「In April 2018, we launched Hepalyse W Premium Kiwami as the top-end product in the series, strengthening the product lineup.」

「In April 2018, we launched Hepalyse W Premium Kiwami, strengthening the product lineup.」

「During the consolidated fiscal year, we launched 2 new products, Hepalyse Super tablets and Hepalyse W Premium tablets, strengthening the product lineup. In addition, we began shipping Hepalyse W Premium Kiwami in March of the same year, ahead of its launch in April 2018.」

「In October 2017, we launched Hepalyse Super tablets and Hepalyse W Premium tablets, strengthening the product lineup.」

「In October 2016, we launched Hepalyse King Plus (Class 2 OTC drug) and Hepalyse King EX (Class 2 OTC drug) as premium mini tonic drinks for drugstores, strengthening the product lineup.」

「In particular, the new Hepalyse W Premium product for convenience stores launched in March last year, and the mini tonic drinks for drugstores Hepalyse King Plus (Class 2 OTC drug) and Hepalyse King EX (Class 2 OTC drug), launched in October last year, made significant contributions to the increase in sales.」

「To strengthen the Hepalyse product lineup, we began shipping Hepalyse King Plus (Class 2 OTC drug) and Hepalyse King EX (Class 2 OTC drug), mini tonic drinks for drugstores scheduled for launch in October this year, in September. For the Chondroitin series, we maintained an overwhelmingly strong market share as a result of sales activities emphasizing its efficacy, safety and high quality as a drug and clearly distinguishing it from health foods. In addition, to strengthen the With One series lineup, we launched With One Suppository (Class 3 OTC drug), a suppository laxative, for pharmacies and drugstores nationwide in September this year.」

「In particular, Hepalyse W Premium, launched in March 2016 to strengthen the lineup of Hepalyse W products for convenience stores, has performed well.」

「To strengthen the lineup of Hepalyse W products for convenience stores, we launched Hepalyse W Sparkling (carbonated beverage) in June 2015 and Hepalyse W Premium (soft drink) in March 2016. In addition, to strengthen the Hepalyse series of OTC tonic products, we launched Hepalyse Plus II in October 2015.」